BeyondSpring Inc is engaged in clinical stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. The Company has created Plinabulin which is marine derived small-molecule with a number of distinct biological activities... BeyondSpring Inc is engaged in clinical stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. The Company has created Plinabulin which is marine derived small-molecule with a number of distinct biological activities that may provide multiple therapeutic opportunities. Plinabulin has increased the survival of neutrophils, a type of white blood cell important in the prevention of bacterial infections. The Company has a scalable business model integrating clinical resources in the United States and China. Show more
FLORHAM PARK, N.J., Nov. 11, 2024 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (βBeyondSpringβ or the βCompanyβ), a clinical-stage global biopharmaceutical company developing innovative...
FLORHAM PARK, N.J., Sept. 16, 2024 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (βBeyondSpringβ or the βCompanyβ), a clinical-stage global biopharmaceutical company developing innovative...
- Statistically Significant and Clinically Meaningful Efficacy Data with Favorable Benefit/Risk ratio from DUBLIN-3 Phase 3 Study of Plinabulin plus Docetaxel vs. Docetaxel in EGFR Wild-Type NSCLC...
FLORHAM PARK, N.J., Sept. 03, 2024 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (βBeyondSpringβ or the βCompanyβ), a clinical-stage global biopharmaceutical company focused on developing...
The SEED-Eisai Research Collaboration leverages Eisaiβs leading expertise in neurodegeneration and cancer. SEED is entitled to receive upfront and milestone payments of up to $1.5 billion plus...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.1107 | 7.14193548387 | 1.55 | 1.75 | 1.43 | 42572 | 1.60124629 | CS |
4 | -0.2393 | -12.5947368421 | 1.9 | 1.94 | 1.43 | 34759 | 1.63787164 | CS |
12 | -0.8693 | -34.3596837945 | 2.53 | 2.5312 | 1.43 | 26025 | 1.86955176 | CS |
26 | -0.7693 | -31.658436214 | 2.43 | 2.6 | 1.43 | 25846 | 2.01266391 | CS |
52 | 0.8307 | 100.084337349 | 0.83 | 4 | 0.7777 | 83147 | 2.53888405 | CS |
156 | -3.2393 | -66.1081632653 | 4.9 | 5.175 | 0.542 | 235644 | 2.22906109 | CS |
260 | -13.3793 | -88.9581117021 | 15.04 | 33 | 0.542 | 456118 | 13.1475555 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.